SCHEMBL680640

SCHEMBL680640

CS(=O)(=O)c1ccc(-c2cc3[nH]ncc3cc2Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)cc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MET P08581 16/20 0.55
RIPK3 Q9Y572 2/20 0.55
AXL P30530 7/20 0.55
TYRO3 Q06418 4/20 0.55
MERTK Q12866 4/20 0.55
ABL1 P00519 1/20 0.54
MST1R Q04912 1/20 0.54
LCK P06239 1/20 0.53
KIT P10721 1/20 0.53
KDR P35968 1/20 0.53
FLT3 P36888 1/20 0.53
RIPK1 Q13546 1/20 0.53
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680387 0.88 MET (0.62) METRIPK3AXLTYRO3MERTK
SCHEMBL701942 0.87 AXL (0.57) METRIPK3AXLTYRO3MERTK
SCHEMBL2492894 0.84 MET (0.64) METRIPK3AXLTYRO3MERTK
SCHEMBL680268 0.82 AXL (0.55) METRIPK3AXLTYRO3MERTK
SCHEMBL681138 0.82 AXL (0.61) METRIPK3AXLTYRO3MERTK
SCHEMBL681035 0.80 AXL (0.55) METAXLTYRO3MERTK
SCHEMBL680709 0.80 AXL (0.58) METRIPK3AXLTYRO3MERTK
SCHEMBL680684 0.79 AXL (0.56) METRIPK3AXLTYRO3MERTK
SCHEMBL680685 0.79 AXL (0.56) METRIPK3AXLTYRO3MERTK
SCHEMBL680889 0.78 MET (0.64) METAXLTYRO3MERTKMST1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC MET 1/4885RIPK3 1295/4885AXL 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.